Review Article: Liver Transplantation for Acute Liver Failure- Indication, Prioritization, Timing, and Referral

Acute liver failure (ALF) is a major success story in gastroenterology, with improvements critical care and transplant resulting significant patient outcomes the current era compared to dismal survival rates pretransplant era. However, ever-increasing list of candidates limited organ pool makes judicious selection use mandatory achieve good prevent wastage. Several scoring systems exist facilitate identification patients who need would therefore an early referral specialized unit. The timing also crucial as transplanting too lead those recover spontaneously receiving (wastage), late decision might result becoming unfit for (delisted) or have advanced disease which poor post-transplant outcomes. article reviews indications contraindications ALF patients, various prognostic systems, etiology-specific outcomes, prioritization referral. potentially fatal complication severe hepatic illness. Most definitions define by presence encephalopathy coagulopathy—International normalized ratio (INR) > 1.5 prothrombin time >15 s) without pre-existing disease. may be classified based on differences interval between onset symptoms encephalopathy, has significance (Table 1).1Shalimar Acharya Subrat K. Lee William M. Worldwide acute failure.in: Critical Care Liver Failure. Future Medicine Ltd, 2013: 32-46http://www.futuremedicine.com/doi/abs/10.2217/ebo.12.326Date accessed: May 15, 2016Crossref Google ScholarTable 1Classification Based Interval Between Jaundice Encephalopathy.O'Grady System2O'Grady J.G. Schalm S.W. Williams R. failure: redefining syndromes.Lancet. 1993; 342: 273-275https://doi.org/10.1016/0140-6736(93)91818-7Abstract PubMed Scopus (791) ScholarWeeks from jaundice encephalopathyHyperacute0–1Acute1–4Subacute4–12Bernuau System3Bernal W. Wendon J. failure.N Engl J Med. 2013; 369: 2525-2534https://doi.org/10.1056/NEJMra1208937Crossref (716) ScholarFulminant0–2Subfulminant2–12Japanese Classification3Bernal ScholarFulminant0–8(a)AcuteWithin 10 days(b)Subacute11 days 8 weeksLate-onset8–12 Open table new tab rare condition, United States Kingdom annually reporting approximately 2000 400 cases ALF, respectively.4Polson W.M. AASLD position paper: management failure.Hepatology. 2005; 41: 1179-1197https://doi.org/10.1002/hep.20703Crossref (736) Scholar,5Khashab Tector A.J. Kwo P.Y. Epidemiology failure.Curr Gastroenterol Rep. 2007; 9: 66-73https://doi.org/10.1007/s11894-008-0023-xCrossref (108) Scholar It can precipitated multitude factors regional global 2). Thus, while viral hepatitis leading cause India, acetaminophen (APAP) overdose, autoimmune (AIH) other metabolic diseases contribute burden Europe America.1Shalimar Scholar,6Acharya S.K. Indian perspective.Clin Dis. 2021; 18: 143-149https://doi.org/10.1002/cld.1135Crossref (1) Stravitz et al. reported that it predominantly affects women median age group 37–53.7Stravitz R.T. failure.Lancet. 2019; 394: 869-881https://doi.org/10.1016/S0140-6736(19)31894-XAbstract Full Text PDF (265) Up 30% are cryptogenic (also known idiopathic/seronegative/non-A, non-E hepatitis).8Brennan P.N. Donnelly M.C. Simpson K.J. Systematic review: non A-E, seronegative indeterminate hepatitis; what this deadly disease?.Aliment Pharmacol Ther. 2018; 47: 1079-1091https://doi.org/10.1111/apt.14566Crossref (16) Scholar,9Shalimar Kumar al.Acute non–A-E etiology—profile, prognosis, predictors outcome.J Clin Exp Hepatol. 2020; 10: 453-461https://doi.org/10.1016/j.jceh.2019.12.008Abstract (4) In pre-transplant era, short-term mortality was very high (approximately 80–85%) treatment supportive care, therapy directed toward inciting agent, when identifiable.10Bernuau Rueff B. Benhamou J.P. Fulminant subfulminant causes.Semin 1986; 6: 97-106https://doi.org/10.1055/s-2008-1040593Crossref (532) earliest theoretical possibility transplantation (LT) considered National Institutes Health consensus 1983.11National health development conference statement: transplantation--june 20-23, 1983.Hepatol Baltim Md. 1984; 4: 107S-110SCrossref (259) This followed several single-center experiences LT but no randomized controlled trials.12Chapman R.W. Forman D. Peto Smallwood failure?.Lancet. 1990; 335: 32-35https://doi.org/10.5555/uri:pii:0140673690901504Abstract (0) All these studies concluded received urgent transplants had better than did not receive transplants. overall such were worse elective end-stage disease.13Donnelly Hayes P.C. changing face assessment status implications future practice.Liver Transplant. 2016; 22: 527-535https://doi.org/10.1002/lt.24403Crossref Scholar,14Germani G. Theocharidou E. Adam al.Liver Europe: over 20years ELTR database.J 2012; 57: 288-296https://doi.org/10.1016/j.jhep.2012.03.017Abstract (164) 2Etiologies Failure.6Acharya ScholarEtiologies FailureExamplesViral HepatitisHepatitis A, B, C, D, E, Cytomegalovirus, Epstein–Barr Virus, Herpes Simplex, Varicella Zoster, AdenovirusDrug-inducedAcetaminophen (APAP), Isoniazid, Ketoconazole, MDMA (Ecstasy), Nitrofurantoin, Rifampin, Herbal medicationsAutoimmune Hepatitis–Metabolic DiseaseWilson's DiseaseVascular Diseases LiverBudd-Chiari Syndrome, Veno-occlusive liverPregnancy-related failureAcute fatty pregnancy, Pre-eclampsia (HELLP syndrome)Malignant infiltrationBreast cancer, small cell lung lymphoma, melanoma, myelomaToxin exposureMushroom, rat poison, toxic agentsMiscellaneousPartial hepatectomy, heat stroke, sepsis, hemophagocytic lymphohistiocytosisMDMA, 3,4-methylenedioxymethamphetamine; HELLP, Hemolysis, elevated enzymes, low platelets MDMA, Current guidelines advocate center should contacted at stage all having plans place transfer expert arise.4Polson Scholar,15Wendon Cordoba Dhawan A. al.EASL Clinical Practical Guidelines (fulminant) failure.J 2017; 66: 1047-1081https://doi.org/10.1016/j.jhep.2016.12.003Abstract (405) Network Organ Sharing (United America) recognizes unique terms mortality. designates “Status 1”, highest priority list.16McDiarmid S.V. Goodrich N.P. Harper A.M. Merion R.M. 1: consequences intentions.Liver 13: 699-707https://doi.org/10.1002/lt.21125Crossref (25) Patients 1” usually admitted intensive unit either renal (on hemodialysis) respiratory mechanical ventilation) INR>2 within weeks initial These likely survive period >7 days.17Martin P. DiMartini Feng S. Brown Fallon Evaluation adults: 2013 practice guideline American association study society transplantation.Hepatology. 2014; 59: 1144-1165https://doi.org/10.1002/hep.26972Crossref (549) By virtue their listing, bypass chronic illnesses (who been longer duration). Although listing does guarantee transplant, waiting times 48–72 h organ.18Nephew L.D. Zia Z. Ghabril al.Sex disparities waitlisting failure.JHEP 3100200https://doi.org/10.1016/j.jhepr.2020.100200Abstract Scholar,19Lee Squires R.H. Nyberg S.L. Doo Hoofnagle J.H. summary workshop.Hepatology. 2008; 1401-1415https://doi.org/10.1002/hep.22177Crossref (542) accounted 8% (1988–2009) 3.9% orthotopic (1995–2005).13Donnelly Scholar,20Adam Karam V. Delvart al.Evolution results Europe. A report European Transplant Registry (ELTR).J 675-688https://doi.org/10.1016/j.jhep.2012.04.015Abstract (619) past 3 decades, there improvement medicine translated into higher transplant-free (TFS) almost 50% ALF.21Koch D.G. Tillman H. Durkalski Reuben Development model predict failure.Clin 14: 1199-1206.e2https://doi.org/10.1016/j.cgh.2016.03.046Abstract (61) 1- 5-year after 79% 72%, respectively; continues TFS rates. recent indicate LT, some improve only.14Germani 1995 indicated 20% transplanted unnecessarily.22Lake J.R. Sussman N.L. Determining prognosis fulminant you absolutely, positively know answer.Hepatology. 1995; 21: 879-882https://doi.org/10.1002/hep.1840210339Crossref unnecessary only deny organs add pressure using marginal ABO-incompatible grafts meet list.23Yoon Y.I. Song G.W. S.G. al.Outcome adult living-donor hepatocellular carcinoma.J 68: 1153-1162https://doi.org/10.1016/j.jhep.2018.02.002Abstract Scholar,24Zhang T. Dunson Kanwal F. al.Trends allografts transplant.JAMA Surg. 155: 926-932https://doi.org/10.1001/jamasurg.2020.2484Crossref (24) review focuses indication, prioritization, timing, transplant. As discussed previously, ideally reserved alone. underscores robust models portend outcome referred LT.25Wong N.Z. Reddy K.R. Bittermann etiology independent predictor waitlist posttransplantation national cohort.Liver 2022; 28: 39-50https://doi.org/10.1002/lt.26187Crossref (5) most common etiologies drugs. Among etiologies, E predominant, cytomegalovirus, varicella zoster virus, herpes simplex Dengue virus less common. effective vaccination against B led reduction incidence, important south Asia.26Jayaraman Y.Y. Chan W.K. Mahadeva Epidemiological conditions Asia West.JGH Open. 332-339https://doi.org/10.1002/jgh3.12275Crossref (10) Less 5% HBV infection progress 25%.27Xiong Q.F. Xiong Huang Zhong Y.D. Wang H.L. Yang Y.F. Early progression failure.PLoS One. 13e0201049https://doi.org/10.1371/journal.pone.0201049Crossref (6) Scholar,28Ichai Samuel Management B.Curr Infect Dis 25https://doi.org/10.1007/s11908-019-0682-9Crossref availability oral nucleos(t)ide analogs provides opportunity intervention injury, preventing ALF. still HBV-ALF Hepatitis E-related ALF.29Patterson Hussey H.S. Abdullahi L.H. al.The epidemiology viral-induced systematic protocol.BMJ 9e029819https://doi.org/10.1136/bmjopen-2019-029819Crossref Scholar,30Shalimar Kedia Gunjan due associated patients.Dig Sci. 62: 1058-1066https://doi.org/10.1007/s10620-017-4461-xCrossref HBV-ALF, 88.0% 85.0%, respectively 3).31Jung D.H. Hwang Lim Y.S. comparison A-related versus B-related recipients.Clin 32e13140https://doi.org/10.1111/ctr.13140Crossref (8) 3Available Data Transplant-free Survival Post-LT Etiology.AuthorEtiologyTransplant free survivalSurvival post-Liver Transplant1-year5-yearLee 19Lee ScholarJung 31Jung ScholarTaylor 34Taylor Davern Munoz al.Fulminant States: outcomes.Hepatology. 2006; 44: 1589-1597https://doi.org/10.1002/hep.21439Crossref (145) ScholarHepatitis A57–69%69%69%Lee ScholarXiong 27Xiong ScholarIchai 28Ichai B25%88%85%Shalimar 30Shalimar E55.1%NANAWong 25Wong ScholarAcetaminophen related65%NANAKumar 44Kumar Shalimar Bhatia al.Antituberculosis therapy–induced magnitude, profile, outcome.Hepatology. 2010; 51: 1665-1674https://doi.org/10.1002/hep.23534Crossref (120) ScholarAnti tubercular related29.6%NANAWong ScholarReuben 42Reuben Koch Drug-induced U.S. Multicenter, prospective study.Hepatol 52: 2065-2076https://doi.org/10.1002/hep.23937Crossref (513) ScholarOther drug/agent27.1%75.6–92.6%60%Wong ScholarFutagawa 48Futagawa Y. Terasaki P.I. An analysis OPTN/UNOS registry.Clin Transpl. 2004; (Published online): 315-329PubMed ScholarKrawitt 49Krawitt E.L. Autoimmune hepatitis.N 354: 54-66https://doi.org/10.1056/NEJMra050408Crossref (713) ScholarAutoimmune hepatitisNA77.1%50.2%Pawaria 59Pawaria Sood Lal B.B. Khanna Bajpai Alam Ninety volume plasma exchange Wilson presenting Apher. 36: 109-117https://doi.org/10.1002/jca.21848Crossref ScholarStankiewicz 60Stankiewicz Patkowski Zieniewicz Diagnostic dilemma Wilson's disease.Ann 26: e930146-1-e930146-6https://doi.org/10.12659/AOT.930146Crossref ScholarCatana 61Catana Medici disease.World 5-10https://doi.org/10.4254/wjh.v4.i1.5Crossref (41) ScholarWilson's Disease47.3%74.4–90.3%89.7% (HAV) (HEV) enteric hepatotropic viruses responsible causing Factors HAV-ALF include male sex, 40 years, undetectable HAV load, serum bilirubin levels, underlying cirrhosis, long hospital stay.32Rezende Roque-Afonso al.Viral clinical course infection.Hepatology. 2003; 38: 613-618https://doi.org/10.1053/jhep.2003.50366Crossref (147) Scholar,33Chen C.M. Chen S.C.C. H.Y. S.T. Hospitalization Taiwan: 15-year nationwide cohort study.J Viral Hepat. 23: 940-945https://doi.org/10.1111/jvh.12564Crossref 57–69%, requiring care.31Jung Scholar,34Taylor Patient 69.0% post-transplant, respectively.31Jung HEV infections caused genotypes 1 2 developing world (which waterborne) autochthonous genotype 4 more Western world.35Legrand-Abravanel Kamar N. Sandres-Saune al.Characteristics solid-organ recipients France.J 202: 835-844https://doi.org/10.1086/655899Crossref (159) largely benign transaminitis requires care. retrospective 1462 29 year tertiary found account 28.7% world, where emerging (prevalence being 10–15% Germany <1% USA).36Fontana R.J. Engle R.E. Gottfried al.Role north injury.Clin Transl Gastroenterol. 11e00273https://doi.org/10.14309/ctg.0000000000000273Crossref (2) Scholar,37Manka Bechmann L.P. Coombes J.D. al.Hepatitis possible Europe.Clin 2015; 13 (quiz e157-158): 1836-1842.e2https://doi.org/10.1016/j.cgh.2015.04.014Abstract 55.1%.30Shalimar incidence pregnant females (22%) non-pregnant males (1–2%).38Shalimar pregnancy.J 3: 213-224https://doi.org/10.1016/j.jceh.2013.08.009Abstract (44) Advanced age, female bilirubin, cerebral edema, prolonged time, in-hospital HEV-related ALF.30Shalimar drugs implicated drug-induced injury (DILI). agents APAP, anti-tuberculosis (isoniazid, rifampicin, pyrazinamide), antibiotics (nitrofurantoin, ketoconazole), anti-epileptics (phenytoin, valproate), recreational agents, herbal complementary medications, so on. APAP overdose one causes DILI West accounts close 13.8% States.39Fontana including overdose.Med North Am. 92: 761-794https://doi.org/10.1016/j.mcna.2008.03.005Abstract (173) Scholar,40Simpson Bates Henderson N.C. utilization non-acetaminophen etiologies.Liver 2009; 15: 600-609https://doi.org/10.1002/lt.21681Crossref (83) One largest involving 22 centers 6 years 42% APAP-related. 65%, remaining LT. N-acetylcysteine stages APAP-induced further improved TFS, now dysfunction.41Lee Hynan L. Rossaro al.Intravenous improves NON-acetaminophen failure.Gastroenterology. 137: 856-864.e1https://doi.org/10.1053/j.gastro.2009.06.006Abstract (441) multicentric 1198 enrolled 10.5 revealed 11.1% drug-related (of diagnosis highly 81% cases). commonly antimicrobials (46% cases), (27.1%). Of these, 56 whom 52 (92.8%) survived episode.42Reuben significantly attributed dose-related short latency, rapid presentation (hyperacute ALF), present slow, subacute, protracted course,